NEWS

WIRES

OTHER

BSD Medical Announces Recognition of Dr. Jacoba van der Zee for Her Pioneering Work in Hyperthermia in the Netherlands

Dr. van der Zee has been instrumental in the development of hyperthermia from a promising field of research to an accepted therapy for the treatment of cancer. She was instrumental in successful completion of a number of clinical studies that demonstrated the safety and effectiveness of the use of hyperthermia for the treatment of certain cancers, including the clinical trial on breast cancer, which was a joint effort with British and Canadian researchers and was published in the International Journal of Radiation Oncology, Biology and Physics, and the randomized Dutch Deep Hyperthermia Trial on pelvic tumors of the rectum, bladder, and cervix, which was published in The Lancet. A number of the clinical studies used BSD's hyperthermia systems. Her achievements were instrumental in establishing hyperthermia and radiotherapy as standard of care in The Netherlands for the treatment of cervical cancer, recurrent breast cancer, melanoma, and head and neck cancer. Dr. van der Zee has also played a leading role in the European Society of Hyperthermic Oncology (ESHO) and served as its President from 1996 through 2000.

"We are pleased that the extraordinary achievements and the decades of leadership and service of Dr. van der Zee have been officially recognized. Dr. van der Zee has had a successful and far-reaching career as a physician, researcher, and leader, and her exceptional service to the field of hyperthermia has significantly improved the lives of cancer patients throughout the world," said Harold R. Wolcott, President of BSD. "We applaud her achievements."

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD's product lines include both hyperthermia and ablation treatment systems. BSD's hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD's microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property and well established distribution in the United States, Europe and Asia. Certain of the Company's products have received regulatory approvals and clearances in the United States, Europe and China. For further information, visit BSD Medical's website at www.BSDMedical.com.

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.

BSD Medical Corporation
Dennis Gauger, 801-972-5555
investor@bsdmc.com
Fax: 801-972-5930